For Healthcare Professionals

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

clipboard-pencil

About the study

This is a Phase 2, multicenter, open-label, single arm study evaluating the safety and efficacy of trilaciclib administered prior to sacituzumab govitecan-hziy in patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received at least 2 prior treatments, at least 1 in the metastatic setting.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Adult ( ≥18 years of age), fFemale or male patient with measurable (per RECIST v1.1), unresectable locally advanced or metastatic TNBC
  2. Documentation of histologically or cytologically confirmed ER-negative, PR-negative, and HER2-negative tumor per the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (ASCO/CAP) criteria.
  3. Patient must have had documented disease progression during or after 2 lines of systemic chemotherapy treatment for unresectable, locally advanced or metastatic breast cancer (these regimens will qualify regardless of TNBC status at the time they were administered):
  4. One prior line of chemotherapy treatment could be in the neoadjuvant or adjuvant setting if progression occurred within 12 months of completion of chemotherapy;
  5. Patients must have prior taxane treatment in either the neoadjuvant, adjuvant, or advanced/metastatic setting OR patients must have demonstrated contraindications or are intolerant to taxanes;
  6. PARP inhibitors may meet the criteria for one of two lines of therapy if patient has documented germline BRCA1/BRCA2 mutation.
  7. ECOG performance status of 0 or 1.
  8. Adequate organ function as demonstrated by the following laboratory values:
  9. Hemoglobin ≥9.0 g/dL
  10. Absolute neutrophil count (ANC) ≥1.5 × 109/L;
  11. Platelet count ≥100 × 109/L;
  12. Estimated glomerular filtration rate ≥30 mL/minute/1.73 m2;
  13. Total bilirubin ≤1.5 × upper limit of normal (ULN);
  14. ALT and AST ≤3 × ULN in the absence of liver metastasis or ≤5 × ULN in the presence of liver metastasis.
  15. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.

EXCLUSION CRITERIA

  1. Prior treatment with trilaciclib, sacituzumab govitecan-hziy, irinotecan, Trop-2 antibody drug conjugate, or any therapy with a topoisomerase-1 payload.
  2. Patients with known brain metastasis at enrollment.
  3. Patients with known Gilbert's disease or known homozygous for the UGT1A1*28 allele.
  4. Patients with bone-only disease.
  5. Malignancies other than TNBC within 3 years prior to enrollment.
  6. History of clinically significant gastrointestinal bleeding, intestinal obstruction, or gastrointestinal perforation within 6 months of enrollment.
  7. Receipt of any high dose systemic corticosteroids within 2 weeks prior to the first dose of study treatment.
  8. Current use of immunosuppressive medication.
  9. Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure (Class III or IV as defined by the New York Heart Association functional classification system).
  10. History of stroke or cerebrovascular accident within 6 months prior to first dose of study treatment.
  11. Serious active infection or severe infection within 4 weeks prior to enrollment.
  12. Prior hematopoietic stem cell or bone marrow transplantation.
  13. Pregnant or lactating women
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 919-213-9835Email iconEmail Study Center

Study’s details


Contition

Triple Negative Breast Cancer

Age

18+

Phase

Phase 2

Participants needed

30

Est. Completion Date

Jul 2024

Treatment type

Interventional


Sponsor

G1 Therapeutics, Inc.

ClinicalTrials.gov identifier

NCT05113966

Study number

G1T28-213

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.